Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T88338
|
||||
Former ID |
TTDS00217
|
||||
Target Name |
23S rRNA
|
||||
Synonyms |
Plastid 23S rRNA; RrnL
|
||||
Target Type |
Successful
|
||||
Disease | Bacterial infections [ICD9: 001-009, 010-018, 020-027, 030-041, 080-088, 090-099, 100-104; ICD10: A00-B99] | ||||
Gram-positive bacterial infection [ICD9: 001-009, 010-018, 020-027, 030-041, 080-088, 090-099, 100-104] | |||||
Pneumonia; Bacterial infections [ICD9: 001-009, 001-139, 010-018, 020-027, 030-041, 080-088, 090-099, 100-104, 480-486, 770.0; ICD10: J12-J18] | |||||
Target Validation |
T88338
|
||||
Drugs and Mode of Action | |||||
Drug(s) | Linezolid | Drug Info | Approved | Bacterial infections | [536773] |
Macrolides | Drug Info | Approved | Bacterial infections | [536854] | |
Spiramycin | Drug Info | Approved | Bacterial infections | [551871] | |
Thiamphenicol | Drug Info | Approved | Bacterial infections | [551871] | |
Cethromycin | Drug Info | Phase 3 | Pneumonia; Bacterial infections | [536773] | |
Oxazolidinones | Drug Info | Phase 2 | Gram-positive bacterial infection | [522273] | |
References | |||||
Ref 522273 | ClinicalTrials.gov (NCT00646958) Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections. U.S. National Institutes of Health. | ||||
Ref 536773 | How many modes of action should an antibiotic have? Curr Opin Pharmacol. 2008 Oct;8(5):564-73. Epub 2008 Jul 30. | ||||
Ref 529611 | The fused TrpEG from Streptomyces venezuelae is an anthranilate synthase, not a 2-amino-2-deoxyisochorismate [corrected] (ADIC) synthase. Ethn Dis. 2008 Spring;18(2 Suppl 2):S2-9-13. | ||||
Ref 534883 | Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors. RNA. 1999 Jul;5(7):939-46. | ||||
Ref 536773 | How many modes of action should an antibiotic have? Curr Opin Pharmacol. 2008 Oct;8(5):564-73. Epub 2008 Jul 30. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.